New antibody TRL345 tested in healthy volunteers for first time
NCT ID NCT05408091
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a single dose of TRL345, an antibody designed to fight cytomegalovirus (CMV), in 16 healthy adults. The main goal was to check safety and how the body processes the drug. Results will help plan future studies in transplant patients who are at high risk for CMV infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TRL345 (a human monoclonal antibody against cytomegalovirus)
- What this could lead to
- If successful, this study could help determine a safe dose of TRL345 for future trials in transplant patients at risk of cytomegalovirus infection.
- What could go wrong
- This is a very early Phase 1 trial with only 16 healthy volunteers, so results may not predict safety or effectiveness in actual patients. The antibody may not work as hoped in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults